HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for
Related Questions
What are the expected timelines for readout of the REVERT IPF Phase 2 trial data?
How will the completion of enrollment impact the company's cash burn and runway through 2026?
What are the projected market size and potential revenue for TTI-101 in idiopathic pulmonary fibrosis?
Did the Q2 2025 financial results meet or miss consensus estimates, and what drove any variance?
How does Tvardi's STAT3 platform differentiate from competitors' fibrosis therapeutics pipelines?
What regulatory milestones (e.g., IND filing, FDA meetings) are anticipated before potential Phase 3 initiation?
Will the company provide guidance on future enrollment milestones or subsequent trial phases for TTI-101?
Are there any upcoming partnership or licensing discussions related to TTI-101 or other STAT3 programs?
How might the REVERT IPF trial results influence the valuation of Tvardi's stock relative to peers in the biotech sector?